MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 19.02.2026
Madrigal Pharmaceuticals Langfristiger Schuldenstrom 2011-2026 | MDGL
Langfristiger Schuldenstrom Jährlich Madrigal Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.02 M | 983 K | 527 K | 602 K | 410 K | 318 K | 315 K | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.02 M | 315 K | 596 K |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
BioLineRx Ltd.
BLRX
|
522 K | $ 2.25 | 1.81 % | $ 908 M |  Israel |
 |
BioNTech SE
BNTX
|
45 M | $ 91.28 | 0.11 % | $ 27.2 B |  Germany |
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | Germany |
 |
Alnylam Pharmaceuticals
ALNY
|
45.5 M | $ 330.34 | 3.6 % | $ 43.3 B |  USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
440 K | $ 0.44 | -16.64 % | $ 5.04 M | Israel |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Catalyst Pharmaceuticals
CPRX
|
437 K | $ 24.98 | 1.17 % | $ 3.05 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
1.63 M | $ 10.14 | -0.29 % | $ 135 M | USA |
 |
Cardiff Oncology
CRDF
|
730 K | $ 1.58 | - | $ 106 M | USA |
 |
Curis
CRIS
|
1.19 M | $ 0.53 | -3.07 % | $ 6.98 M | USA |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
6.49 M | $ 37.7 | 1.26 % | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
18.6 M | $ 49.15 | -0.73 % | $ 4.42 B |  Schweiz |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
CytomX Therapeutics
CTMX
|
4.24 M | $ 4.4 | -3.51 % | $ 607 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
242 K | $ 0.86 | 0.67 % | $ 5.79 M | USA |
 |
Cue Biopharma
CUE
|
1.91 M | $ 0.18 | -1.61 % | $ 17.1 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | USA |
 |
Aquestive Therapeutics
AQST
|
631 K | $ 4.09 | -0.97 % | $ 437 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
3.29 M | $ 4.15 | -32.52 % | $ 10.4 M | USA |
 |
Daré Bioscience
DARE
|
603 K | $ 1.81 | 4.02 % | $ 20.2 M | USA |
 |
DBV Technologies S.A.
DBVT
|
1.12 M | $ 20.36 | -3.32 % | $ 2.84 B |  France |
 |
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
4.21 M | $ 8.22 | 2.37 % | $ 225 M | Israel |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
Denali Therapeutics
DNLI
|
8.31 M | $ 19.38 | -6.15 % | $ 3.19 B | USA |
 |
Dyadic International
DYAI
|
34.6 K | $ 0.87 | -2.8 % | $ 31.5 M | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B |  Britain |
 |
Celldex Therapeutics
CLDX
|
1.55 M | $ 31.37 | 1.0 % | $ 2.08 B | USA |